Table 1.
Patient Characteristics
| Characteristic | Allo-HCT Recipients | Healthy Controls (N = 86) | Overall (N = 196) | |||
|---|---|---|---|---|---|---|
| 3-6 mo (N = 28) | 6-12 mo (N = 15) | >12 mo (N = 67) | All (N = 110) | |||
| Age group, n (%) | ||||||
| <45 yr | 7 (25) | 5 (33.3) | 14 (20.9) | 26 (23.6) | 67 (77.9) | 93 (47.4) |
| 45-65 yr | 16 (57.1) | 7 (46.7) | 38 (56.7) | 61 (55.5) | 19 (22.1) | 80 (40.8) |
| >65 yr | 5 (17.9) | 3 (20) | 15 (22.4) | 23 (20.9) | 0 (0) | 23 (11.7) |
| Sex, n (%) | ||||||
| Male | 19 (67.9) | 9 (60) | 41 (61.2) | 69 (62.7) | 20 (23.3) | 89 (45.4) |
| Female | 9 (32.1) | 6 (40) | 26 (38.8) | 41 (37.3) | 66 (76.7) | 107 (54.6) |
| Vaccine, n (%) | ||||||
| mRNA-1273 | 7 (25) | 0 (0) | 9 (13.4) | 16 (14.5) | 11 (12.8) | 27 (13.8) |
| BNT162b | 21 (75) | 15 (100) | 58 (86.6) | 94 (85.5) | 75 (87.2) | 169 (86.2) |
| Conditioning regimen, n (%) | ||||||
| MAC | 5 (17.9) | 4 (26.7) | 27 (40.3) | 36 (32.7) | ||
| RIC | 23 (82.1) | 11 (73.3) | 40 (59.7) | 74 (67.3) | ||
| IST, n (%) | ||||||
| No | 3 (10.7) | 6 (40) | 50 (74.6) | 59 (53.6) | ||
| Prophylactic | 14 (50) | 2 (13.3) | 0 (0) | 16 (14.5) | ||
| Therapeutic | 11 (39.3) | 7 (46.7) | 17 (25.4) | 35 (31.8) | ||
| History of acute GVHD, n (%) | ||||||
| None/mild | 20 (71.4) | 10 (66.7) | 50 (74.6) | 80 (72.7) | ||
| Moderate/severe | 8 (28.6) | 5 (33.3) | 17 (25.4) | 30 (27.3) | ||
| Chronic GVHD, n (%) | ||||||
| None/mild | 24 (85.7) | 12 (80) | 48 (71.6) | 84 (76.4) | ||
| Moderate/severe | 4 (14.3) | 3 (20) | 19 (28.4) | 26 (23.6) | ||
| Relapse, n (%) | ||||||
| No | 25 (89.3) | 11 (73.3) | 50 (74.6) | 86 (78.2) | ||
| Yes | 3 (10.7) | 4 (26.7) | 17 (25.4) | 24 (21.8) | ||
| Underlying diagnosis, n (%) | ||||||
| Myeloid | 20 (71.4) | 11 (73.3) | 46 (68.7) | 77 (70) | ||
| Lymphatic | 8 (28.6) | 4 (26.7) | 16 (23.9) | 28 (25.5) | ||
| Other | 0 (0) | 0 (0) | 5 (7.5) | 5 (4.5) | ||
| Donor type, n (%) | ||||||
| MSD | 6 (21.4) | 3 (20) | 23 (34.3) | 32 (29.1) | ||
| MUD | 17 (60.7) | 8 (53.3) | 32 (47.8) | 57 (51.8) | ||
| Haploidentical | 5 (17.9) | 4 (26.7) | 12 (17.9) | 21 (19.1) | ||
| Mismatched | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Graft type, n (%) | ||||||
| PBSCs | 28 (100) | 14 (93.3) | 60 (89.6) | 102 (92.7) | ||
| BM | 0 (0) | 1 (6.7) | 7 (10.4) | 8 (7.3) | ||
MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; MSD, matched sibling donor; MUD, matched unrelated donor; PBSCs, peripheral blood stem cells; BM, bone marrow.